Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurobiological Technologies has enrolled the first patients in an extended-use study of Xerecept. The study will monitor the effects of Xerecept in brain tumor patients being treated for peritumoral brain edema.
Subscribe to our email newsletter
This program will collect safety information and allow the treating physicians to attempt a maximum dexamethasone reduction and possible elimination altogether. Xerecept will be provided to patients until either the drug becomes commercially available or until research in this indication is discontinued.
Dr Lisa Carr, Sr vice president and chief medical officer of NTI, said, “We are pleased to offer the extended-use of this potential dexamethasone-sparing agent to patients in all of our trials.”
Neurobiological Technologies is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized.